Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,529 across all filing types
Latest filing 2025-01-13 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document title explicitly states it concerns 'Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons'. This directly corresponds to insider trading reports or director's dealings. The definition for Director's Dealing (DIRS) is 'Report of personal share transactions by company directors and executives (insider trades)'. Although the document text itself is an announcement referencing attached files, the core subject matter is definitively Director's Dealing, making DIRS the most specific classification, rather than the general RPA or RNS fallback. The document is short and points to attachments, but the subject matter is so specific that DIRS is preferred over RPA/RNS.
2025-01-13 English
Director's Dealing 2024
Director's Dealing Classification · 100% confidence The document title explicitly states "Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons." This directly corresponds to the definition of Director's Dealing (insider trades by management). The content confirms that the company is publishing information received about these transactions and directs the reader to an attached file, but the core subject matter is insider transactions, making 'DIRS' the most specific classification, overriding a general 'RPA' or 'RNS'.
2024-12-25 English
Director's Dealing 2024
Director's Dealing Classification · 100% confidence The document explicitly details 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It lists the name of a director (Leonard Kruimer), their position, the nature of the transaction ('Purchase of shares'), the instrument ('Ordinary shares'), price, volume, and date. This content directly corresponds to insider trading reports or director's dealing disclosures, which maps to the 'Director's Dealing' category (DIRS).
2024-12-25 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'Standard form for notification of major holdings' and details changes in voting rights and share capital crossing a threshold (6.20% on 20 Dec 2024) for the issuer Zealand Pharma AS, filed by The Capital Group Companies, Inc. This structure and content perfectly match the definition of a Major Shareholding Notification, which reports changes in significant ownership levels crossing regulatory thresholds. The corresponding code is MRQ.
2024-12-25 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 98% confidence The document explicitly states it is a "major shareholder announcement" regarding The Capital Group Companies, Inc. holding a specific percentage of voting rights (6.20%). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing thresholds. The filing type code for this is MRQ.
2024-12-25 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a formal announcement from Zealand Pharma A/S regarding the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning their New Drug Application (NDA) for glepaglutide. This type of communication, detailing the outcome of a regulatory submission (specifically a drug approval process) and outlining next steps (dialogue with FDA, European submission plans), is a core component of investor relations and regulatory updates. It is not a full Annual Report (10-K), an Earnings Release (ER) focused purely on financial metrics, or a transcript (CT). Since it is a specific announcement about regulatory interaction and clinical trial outcomes that doesn't fit the other specific categories like M&A (TAR) or Director's Dealing (DIRS), it falls best under the general category for significant regulatory/investor news that isn't a standard financial report. Given the context of a major regulatory decision impacting future product viability, it is a significant announcement. While it relates to clinical data, it is primarily a regulatory outcome announcement. It is too specific for the general 'RNS' fallback, but the closest fit among the provided options for a major, non-financial, non-meeting-related corporate update that isn't a specific legal or management change is often captured by general regulatory/investor news. However, since the core subject is the FDA's decision on a drug application, and it is a formal company announcement, it functions as a significant regulatory update. If a specific 'Regulatory Update' code existed, it would fit there. Given the choices, 'RNS' (Regulatory Filings/General Regulatory Announcements) serves as the best catch-all for significant, non-standard filings that aren't financial reports or management changes. It is a direct communication about a regulatory event.
2024-12-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.